TrialA Study of AL102 in Patients With Progressing Desmoid Tumors
Trial details
- Registry ID
- NCT04871282
- Phase
- Phase 2, Phase 3
IMNM
Immunome, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of AL102 in Patients With Progressing Desmoid TumorsNCT04871282 | IMNM | Phase 2, Phase 3 | Active not recruiting | 2025-12-03Actual |
Latest recorded trial changes
A Study of AL102 in Patients With Progressing Desmoid Tumors
NCT04871282 · Immunome, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Progression free survival
+ After
Measure: Part A: Safety and Tolerability - Adverse Events Measure: Part B: Progression free survival (PFS)
A Study of AL102 in Patients With Progressing Desmoid Tumors
NCT04871282 · Immunome, Inc.
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Oct 2025
+ After
3 Dec 2025